The effect of FAD on erythrocyte glutathione reductase activity in undialyzed uremic patients and healthy subjects

Ari Z., Uyanik B., Yigitoglu M., KUTLU N., Pirim I.

Turkish Journal of Medical Sciences, vol.27, no.1, pp.71-74, 1997 (Scopus, TRDizin) identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 1997
  • Journal Name: Turkish Journal of Medical Sciences
  • Journal Indexes: Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.71-74
  • Keywords: anemia, FAD, glutathione reductase, riboflavin, uremia
  • Manisa Celal Bayar University Affiliated: Yes

Abstract

The erythrocyte glutathione reductase (GSSG-R) activity with and without FAD supplementation (Act. A and Act. B, respectively) was studied in 24 undialyzed uremic patients and 25 healthy subjects. Mean erythrocyte GSSG-R activity from normal subjects was 5.39 ± 1.43 U/g Hb (the active form). After the addition of FAD to the hemolysates, this increased to 7.79 ± 1.07 U/g Hb, an increase of 1.88 ± 0.84 U/g Hb (the inactive from) (p < 0.001). In patients with FAD supplementation, erythrocyte GSSG-R activity increased from 9.26 ± 1.19 U/g Hb to 10.06 ± 1.06 U/g Hb, an increase of 0.80 ± 0.76 U/g Hb (p < 0.01). In addition, there were significant positive correlations between the enzyme activities and plasma urea level, and negative correlations between the enzyme activities and hemoglobin concentrations in patients, but not in the controls. It was concluded that further cross-sectional in vivo studies should be made to determine whether riboflavin administration may or not be useful in preventing renal anemia.